Company news
Proteomics International Laboratories Ltd. (ASX:PIQ) news
Proteomics International Laboratories Ltd. news releases on 6ix. Latest, Mar 23, 2020: Proteomics patents biomarkers for diagnosis of endometriosis
Press releases — page 4
Proteomics patents biomarkers for diagnosis of endometriosis
March 22, 2020
Appendix 4C - December 2019 Quarterly Report
January 28, 2020
CE Mark for PromarkerD Hub predictive software for DKD
January 13, 2020
Partnership provides funding for cutting-edge facility
November 25, 2019
Proteomics raises $3m in heavily oversubscribed Placement
November 14, 2019
CE Mark for predictive test for diabetic kidney disease
November 11, 2019
Appendix 4C - September 2019 Quarterly Report
October 30, 2019
PromarkerD IVD successfully developed and validated
September 17, 2019
PromarkerD diabetic kidney disease test launched in Spain
September 13, 2019
PromarkerD test ready for launch in Europe
September 12, 2019
Appendix 4C - June 2019 Quarterly Report
July 30, 2019
Proteomics secures contracts for pharmacokinetic analysis
July 25, 2019
Appendix 4C - March 2019 Quarterly Report
April 23, 2019
US patent for identifying drugs for abnormal kidney function
February 20, 2019
Appendix 4C - December 2018 Quarterly Report
January 29, 2019
PromarkerD US market update
January 23, 2019
Proteomics signs PromarkerD agreement with US big pharma
November 25, 2018
PromarkerD kit version complete- commercial release imminent
November 8, 2018
Appendix 4C - September 2018 Quarterly Report
October 29, 2018
Diabetic kidney disease test enters Europe & Export Award
October 23, 2018
Proteomics receives $834k in R&D Tax Incentive
October 16, 2018
Proteomics & Atturos partner to target diagnostics in Europe
September 19, 2018
Proteomics to receive $928k from sale of shareholding in CPR
September 12, 2018
Diagnostics update- Pipeline yields potential new biomarkers
August 22, 2018
Appendix 4C - June 2018 Quarterly Report
July 29, 2018
Proteomics secures major contract - nears cash flow positive
July 18, 2018
Further information on new licence deals in USA and Mexico
June 20, 2018
Proteomics signs deal with Patia for PromarkerD in Mexico
June 17, 2018
Proteomics signs deal to launch PromarkerD test in US market
May 28, 2018
Appendix 4C - March 2018 Quarterly Report
April 25, 2018
Europe PromarkerD patent granted for diabetic kidney disease
April 18, 2018
Underwriters take final $342,000 of Proteomics Options
April 16, 2018
Conversion of 90% of Proteomics Options raises of $3m
April 5, 2018
Directors Exercise PIQ Options
March 23, 2018
Proteomics secures underwriting - PIQ Options to raise $3.4m
March 13, 2018
Proteomics launches PromarkerD
March 6, 2018
Strategic alliance and investment in CPR Pharma Services
February 1, 2018
PromarkerD diabetic kidney disease patent granted in Japan
January 28, 2018
Appendix 4C - December 2017 Quarterly Report
January 25, 2018
Proteomics joins major health study to target lung disease
December 3, 2017
PromarkerD predictive diagnostic test to launch in Q1 2018
November 26, 2017
Proteomics partnered consortium to receive $2 million
October 26, 2017
Appendix 4C - September 2017 Quarterly Report
October 25, 2017
Proteomics receives R&D tax incentive
October 9, 2017
PromarkerD predictive test results published - Diabetes Care
September 6, 2017
US PromarkerD patent expanded to all kidney disease
August 16, 2017
Appendix 4C - corrected
July 28, 2017
Appendix 4C - June 2017 Quarterly Report
July 27, 2017
Proteomics wins major analytical services contract
July 14, 2017
Response to ASX Query
June 15, 2017